Fatal fulminant hepatitis associated with Ganoderma lucidum (Lingzhi) mushroom powder

Harirak Wanmuang1, Juvady Leopairut, Chomsri Kositchaiwat

  • 1Department of Pathology, Faculty of Medicine, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand.

Insights

Ganoderma lucidum (Lingzhi) mushroom powder has been linked to severe liver damage, including fatal hepatitis. This risk is heightened when combined with other medications, necessitating careful monitoring.

Area of Science:

  • * Integrative medicine and toxicology.
  • * Herbal medicine safety and adverse event reporting.

Background:

  • * Ganoderma lucidum (Lingzhi) is a widely used medicinal mushroom.
  • * Traditional preparations involve boiling, while modern use includes powdered forms.

Observation:

  • * Two cases of severe hepatotoxicity, including fatal fulminant hepatitis, were observed.
  • * Both patients had previously used boiled Lingzhi without adverse effects.
  • * Hepatotoxicity occurred after 1-2 months of using Lingzhi powder, alongside other medications.

Findings:

  • * Lingzhi mushroom powder was implicated as the causative agent in severe liver injury.
  • * The hepatotoxic effect appeared specific to the powder form, not traditional preparations.
  • * Concurrent use of other therapeutic agents may potentiate the toxicity.

Implications:

  • * The powdered form of Ganoderma lucidum requires cautious use and monitoring for potential hepatotoxicity.
  • * Healthcare providers should be aware of the risks associated with Lingzhi powder, especially in patients on multiple medications.
  • * Further research is needed to elucidate the mechanisms of Lingzhi-induced liver injury.